(R)-3,3,3-trifluoro-2-hydroxy-2-methyl- propionamides are orally active inhibitors of pyruvate dehydrogenase kinase [2]

Journal of Medicinal Chemistry

Volumn 42, Issue 15, 1999, Pages 2741-2746

  Aicher, Thomas D ^a   Anderson, Robert C ^a,b   Bebernitz, Gregory R ^a   Coppola, Gary M ^a   Jewell, Charles F ^a   Knorr, Douglas C ^a   Liu, Charles ^a   Sperbeck, Donald M ^a   Brand, Leonard J ^a   Strohschein, Robert J ^a   Gao, Jiaping ^a   Vinluan, Christine C ^a   Shetty, Suraj S ^a   Dragland, Carol ^a   Kaplan, Emma L ^a   DelGrande, Dominick ^a   Islam, Amin ^a   Liu, Xilin ^a   Lozito, Robert J ^a   Maniara, Wieslawa M ^a   Walter, R Erik ^a   Mann, William R ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Sphinx Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLOROACETIC ACID; METHYLPROPIONAMIDE DERIVATIVE; PYRUVATE DEHYDROGENASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; DECARBOXYLATION; DEPHOSPHORYLATION; DRUG BIOAVAILABILITY; DRUG POTENCY; ENZYME INHIBITION; GLUCOSE METABOLISM; LETTER; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; LACTIC ACID; PROPIONIC ACIDS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033614928     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9902584     Document Type: Letter

References (58)

1. Caterson, I. D.; Kerby, A. L.; Cooney, G. J.; Frankland, R.; Denyer, G. S.; Nicks, J.; Williams, P. F. Inactivation of Pyruvate Dehydrogenase Complex in Heart Muscle Mitochondria of Gold-Thioglucose-Induced Obese Mice is not Due to a Stable Increase in Activity of Pyruvate Dehydrogenase Kinase. Biochem. J. 1988, 253, 291-294.
2. (a) Wieland, O.; Siess, E.; Schulze-Wethmar, F. H.; von Funcke, H. G.; Winton, B. Active and Inactive Forms of Pyruvate Dehydrogenase in Rat Heart and Kidney: Effect of Diabetes, Fasting, and Refeeding on Pyruvate Dehydrogenase Interconversion. Arch. Biochem. Biophys. 1971, 143, 593-601.
3. (b) Denyer, G. S.; Lam, D.; Cooney, G. J.; Caterson, I. D. Effect of Starvation and Insulin In Vivo on the Activity of the Pyruvate Dehydrogenase Complex in Rat Skeletal Muscles. FEBS Lett. 1989, 250, 464-468.
4. Imura, M.; Takatani, O. Short-Term Regulation of Pyruvate Dehydrogenase Complex by Insulin. Horm. Metab. Res. 1981, 13, 267-272.
5. Mondon, C. E.; Jones, I. R.; Azhar, S.; Hollenbeck, C. B.; Reaven, G. M. Lactate Production and Pyruvate Dehydrogenase Activity in Fat and Skeletal Muscle From Diabetic Rats. Diabetes 1992, 41, 1547-1554.
6. Mandarino, L. J.; Consoli, A.; Kelly, D. E.; Reilly, J. J.; Nurjhan, N. Fasting Hyperglycemia Normalizes Oxidative and Nonoxidative Pathways of Insulin-Stimulated Glucose Metabolism in Noninsulin-Dependent Diabetes Mellitus. J. Clin. Endocrinol. Metab. 1990, 71, 1544-1551.
7. Del Prato, S.; Bonadonna, R. C.; Bonora, E.; Gulli, G.; Solini, A.; Shank, M.; DeFronzo, R. A. Characterization of Cellular Defects of Insulin Action in Type 2 (Non-Insulin-Dependent) Diabetes Mellitus. J. Clin. Invest. 1993, 91, 484-494.
8. Henry, R. R.; Thorburn, A. W.; Beerdson, P.; Gumbiner, B. Dose-Response Characteristics of Impaired Glucose Oxidation in Non-Insulin-Dependent Diabetes Mellitus. Am. J. Physiol. 1991, 261, E132-E140.
9. For a review of the structural components of the PDH multienzyme complex, see: Mattevi, A.; De Kok, A.; Perham, R. N. The Pyruvate Dehydrogenase Multienzyme Complex. Curr. Opin. Struct. Biol. 1992, 2, 877-887.
10. Sugden, P. H.; Kerbey, A. L.; Randle, P. J.; Waller, C. A.; Reid, K. B. Amino Acid Sequences Around the Sites of Phosphorylation in the Pig Heart Pyruvate Dehydrogenase Complex. Biochem. J. 1979, 181, 419-426.
11. Yeaman, S. J.; Hutcheson, E. T.; Roche, T. E.; Pettit, F. H.; Brown, J. R.; Reed, L. J.; Watson, D. C.; Dixon, G. H. Sites of Phosphorylation on Pyruvate Dehydrogenase from Bovine Kidney and Heart. Biochemistry 1978, 17, 2364-2370.
12. (a) Popov, K. M.; Kedishvili, N. Y.; Zhao, Y.; Shimomura, Y.; Crabb, D. W.; Harris, R. A. Primary Structure of Pyruvate Dehydrogenase Kinase Establishes a New Family of Eukaryotic Protein Kinases. J. Biol. Chem. 1993, 268, 26602-26606.
13. (b) Popov, K. M.; Kedishvili, N. Y.; Zhao, Y.; Gudi, R.; Harris, R. A. Molecular Cloning of the p45 Subunit of Pyruvate Dehydrogenase Kinase. J. Biol. Chem. 1994, 269, 29720-29724.
14. (c) Gudi, R.; Bowker-Kinley, M. M.; Kedishvili, N. A.; Zhao, Y.; Popov, K. M. Diversity of the Pyruvate Dehydrogenase Kinase Gene Family in Humans. J. Biol. Chem. 1995, 270, 28989-28994.
15. Linn, T. C.; Pettit, F. H.; Reed, L. J. α-Keto Acid Dehydrogenase Complexes. X. Regulation of the Activity of the Pyruvate Dehydrogenase Complex from Beef Kidney Mitochondria by Phosphorylation and Dephosphorylation. Proc. Natl. Acad. Sci. U.S.A. 1969, 62, 234-241.
16. a Kinase by Reduced Nicotinamide Adenine Dinucleotide, Dihydrolipoamide, Acetyl Coenzyme A, or Pyruvate. J. Biol. Chem. 1978, 253, 496-503.
17. Randle, P. J.; Kerbey, A. L.; Espinal, J. Mechanisms of Decreasing Glucose Oxidation on Diabetes and Starvation: Role of Lipid Fuel and Hormones. Diabetes Metab. Rev. 1988, 4, 623-638.
18. a Kinase and Synergistic Inhibition by Pyruvate and ADP. J. Biol. Chem. 1979, 254, 7191-7196.
19. Whitehouse, S.; Cooper, R. H.; Randle, P. J. Mechanism of Activation of Pyruvate Dehydrogenase by Dichloroacetate and other Halogenated Carboxylic Acids. Biochem. J. 1974, 141, 761-774.
20. Stacpoole, P. W.; Moore, G. W.; Kornhauser, D. M. Metabolic Effects of Dichloroacetate in Patients with Diabetes Mellitus and Hyperlipoproteinemia. N. Engl. J. Med. 1978, 298, 526-530.
21. (a) Curry, S. H.; Chu, P. I.; Baumgartner, T. G.; Stacpoole, P. W. Plasma Concentrations and Metabolic Effects of Intravenous Sodium Dichloroacetate. Clin. Pharmacol. Ther. 1985, 37, 89-93.
22. (b) Wells, P. G.; Moore, G. W.; Rabin, D.; Wilkinson, G. R.; Oates, J. A.; Stacpoole, P. W. Metabolic Effects and Pharmacokinetics of Intravenously Administered Dichloroacetate in Humans. Diabetologia 1980, 19, 109-113.
23. Bersin, R. M.; Stacpoole, P. W. Dichloroacetate as Metabolic Therapy for Myocardial Ischemia and Failure. Am. Heart J. 1997, 134, 841-855.
24. Preiser, J. C.; Moulart, D.; Vincent, J. L. Dichloroacetate Administration in the Treatment of Endotoxic Shock. Circ. Shock 1990, 36, 221-228.
25. Granot, H.; Steiner, I. Successful Treatment of Irreversible Hemorrhagic Shock in Dogs with Fructose-1,6-Diphosphate and Dichloroacetate. Circ. Shock 1985, 15, 163-173.
26. Henderson, G. N.; Curry, S. H.; Derendorf, H.; Wright, E. C.; Stacpoole, P. W. Pharmacokinetics of Dichloroacetate in Adult Patients with Lactic Acidosis. J. Clin. Pharmacol. 1997, 37, 416-425.
27. Bersin, R.; Kwasman, M.; DeMarco, T.; Lau, D.; Klinski, C.; Golonka, J.; Chatterjee, K. Improved Hemodynamic Function in Congestive Heart Failure with the Metabolic Agent Sodium Dichloroacetate (DCA). J. Am. Coll. Cardiol. 1990, 15, 157A.
28. Dichloroacetic acid showed efficacy in these indications. For a review of the pharmacology of DCA, see: Stacpoole, P. W. The Pharmacology of Dichloroacetate. Metabolism 1989, 38, 1124-1144.
29. Stacpoole, P. W.; Moore, G. W.; Kornhauser, D. M. Toxicity of Chronic Dichloroacetate. N. Engl. J. Med. 1979, 300, 372.
30. Yount, E. A.; Felten, S. Y.; O'Connor, B. L.; Peterson, R. G.; Powell, R. S.; Yum, M. N.; Harris, R. A. Comparison of the Metabolic and Toxic Effects of 2-Chloropropionate and Dichloroacetate. J. Pharmacol. Exp. Ther. 1982, 222, 501-508.
31. Katz, R.; Tai, C. N.; Diener, R. M.; McConnell, R. F.; Semonick, D. E. Dichloroacetate, Sodium: 3-Month Oral Toxicity Studies in Rats and Dogs. Toxicol Appl. Pharmacol. 1987, 57, 273-287.
32. Toth, G. P.; Kelty, K. C.; George, E. L.; Read, E. J.; Smith, M. K. Adverse Male Reproductive Effects Following Subchronic Exposure of Rats to Sodium Dichloroacetate. Fundam. Appl. Toxicol. 1992, 19, 57-63.
33. Halpert, J. R.; Balfour, C.; Miller, N. E.; Kaminsky, L. S. Dichloromethyl Compounds as Mechanism-Based Inactivators of Rat Liver Cytochromes P 450 In Vitro. Mol. Pharmacol. 1986, 30, 19-24.
34. Bookstaff, R. C.; Moore, R. W.; Ingall, G. B.; Peterson, R. E. Androgenic Deficiency in Male Rats Treated with Perfluorodecanoic acid. Toxicol. Appl. Pharmacol. 1990, 104, 322-333.
35. Espinal, J.; Leesnitzer, T.; Hassman, A.; Beggs, M.; Cobb, J. Inhibition of Pyruvate Dehydrogenase Kinase by Halogenated Acetophenones. Drug Devel. Res. 1995, 35, 130-136.
36. Jackson, J. C.; Vinluan, C. C.; Dragland, C. J.; Sundararajan, V.; Yan, B.; Gounarides, J. S.; Nirmala, N. R.; Topiol, S.; Ramage, P.; Blume, J. E.; Aicher, T. D.; Bell, P. A.; Mann, W. R. Heterologously Expressed Inner Lipoyl Domain of Dihydrolipoyl Acetyltransferase Inhibits ATP-Dependent Inactivation of Pyruvate Dehydrogenase Complex: Identification of Important Amino Acid Residues. Biochem. J. 1998, 334, 703-711.
37. ATP Potassium Channel Openers. Modifications on the Western Region. J. Med. Chem. 1996, 39, 4592-4601.
38. (a) Brieden, W.; Naughton, A.; Robins, K.; Shaw, N.; Tinschert, A.; Zimmermann, T. Enzymic Method for the Stereoselective Preparation of (S)-or(R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acids. Ger. Offen.
39. (b) Konigsberger, K.; Prasad, K.; Repic, O. The Synthesis of (R)-and (S)-α-Trifluoromethyl-α-hydroxycarboxylic Acids via Enzymatic Resolutions. Tetrahedron Asymmetry 1999, 10, 679-687.
40. For the enzymatic resolution of the (S)-enantiomer, see: Crosby, J.; Holt, R. A.; Pittam, J. D. Enzymatic Process for Stereoselective Preparation of Therapeutic Amides. WO9738124-A 97.10.16 (9744).
41. Kelly, S. E.; LaCour, T. G. A One Pot Procedure For the Synthesis of α-Hydroxyamides from the Corresponding α-Hydroxyacids. Synth. Commun. 1992, 22, 859-869.
42. Desai, M.; Watthey, J. W. H.; Zuckerman, M. A Convenient Preparation of 1-Aroylpiperazines. Org. Prep. Proced. Int. 1976, 8, 85-86.
43. (a) Bolos, J.; Gubert, S.; Anglada, L.; Planas, J. M.; Burgarolas, C.; Castello, J. M.; Sacristan, A.; Ortiz, J. A. 7-[3-(1-Piperidinyl)-propoxy]chromenones as Potential Atypical Antipsychotics. J. Med. Chem. 1996, 39, 2962-2970.
44. (b) Morikawa, A.; Sone, T.; Asano, T. 5-Isoquinolinesulfonamide Derivatives. III. Synthesis and Vasodilatory Activity of 1-(5-Isoquinolinesulfonyl)piperazine Derivatives. Chem. Pharm. Bull. 1992, 40, 770-773.
45. For the use of the 2-nitrobenzenesulfonyl moiety as a protecting group for amines, see: (a) Fukuyama, T.; Jow, C.-K.; Cheung, M. 2-and 4-Nitrobenzenesulfonamides: Exceptionally Versatile Means for Preparation of Secondary Amines and Protection of Amines. Tetrahedron Lett. 1995, 36, 6373-6374.
46. (b) Fukuyama, T.; Cheung, M.; Jow, C.-K.; Hidai, Y.; Kan, T. 2,4-Dinitrobenzenesulfonamides: A Simple and Practical Method for the Preparation of a Variety of Secondary Amines and Diamines. Tetrahedron Lett. 1997, 38, 5831-5834.
47. Craig, J. C.; Young, R. J. 1-Benzylpiperazine. Organic Syntheses; Wiley: New York, 1962; Collect. Vol. V, pp 88-91.
48. Craig, J. C.; Young, R. J. 1-Benzylpiperazine. Organic Syntheses; Wiley: New York, 1962; Collect. Vol. V, pp 88-91.
49. Available from Sigma Aldrich Corp., Milwaukee, WI (cat.# P-7032).
50. Inhibition of cAMP-dependent protein kinase was determined using a colorimetric cAMP-dependent protein kinase (PKA) assay kit (Pierce, Rockford, IL; cat.# 26500, SpinZyme format).
51. Young, P. R.; McLaughlin, M. M.; Kumar, S.; Kassis, S.; Doyle, M. L.; McNulty, D.; Gallagher, T. F.; Fisher, S.; McDonnell, P. C.; Carr, S. A.; Huddleston, M. J.; Seibel, G.; Porter, T. G.; Livi, G. P.; Adams, J. L.; Lee, J. C. Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP site. J. Biol. Chem. 1997, 272, 12116-12121.
52. Stock, J. B.; Ninfa, A. J.; Stock, A. M. Protein Phosphorylation and Regulation of Adaptive Responses in Bacteria Microbiol. Rev. 1989, 53, 450-490.
53. An NMR structural determination of the catalytic domain of a prokaryotic histidine protein kinase has been completed; see: Tanaka, T.; Saha, S. K.; Tomomori, C.; Ishima, R.; Liu, D.; Tong, K. I.; Park, H.; Dutta, R.; Qin, L.; Swindells, M. B.; Yamazaki, T.; Ono, A. M.; Kainosho, M.; Inouye, M.; Ikura, M. NMR Structure of the Histidine Kinase Domain of the E. coli Osmosensor EnvZ. Nature 1998, 396, 88-92.
54. Hanks, S. K. Eukaryotic Protein Kinases. Curr. Opin. Struct. Biol. 1991, 1, 369-383.
55. The SAR of the anilides and the design strategy used to optimize them will be discussed in a full report; see: Aicher, T. D.; Bebernitz, G. R.; Stanton, J.; Gao, J.; Shetty, S, S.; Knorr, D. C.; Strohschein, R. J.; Tan, J.; Liu, C.; Brand, L. J.; Yang, W. H.; Vinluan, C. C.; Kaplan, Emma; Dragland, C.; Islam, A.; Lozito, R. J.; Liu, X.; DelGrande, D.; Mann, W. R. Anilides of (R)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionic acid as Inhibitors of Pyruvate Dehydrogenase Kinase. Manuscript in preparation.
56. The SAR of the piperazines and the design strategy to optimize them will be presented in a full report; see: Aicher, T. D.; Anderson, R. C.; Gao, J.; Shetty, S. S.; Coppola, G. M.; Stanton, J. L.; Knorr, D. C.; Sperbeck, D. M.; Brand, L. J.; Vinluan, C. C., Kaplan, E. L.; Dragland, C.; Tomaselli, H. C.; Islam, A.; Lozito, R. J.; Liu, X.; Maniara, W. M.; Fillers, W. S.; DelGrande, D.; Walter, R. E.; Mann, W. R. Secondary Amides of (R)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionic acid as Inhibitors of Pyruvate Dehydrogenase Kinase. Manuscript in preparation.
57. Ofenstein, J. P.; Kiechle, F. L.; Dandurand, D. M.; Belknap, W. M.; Moore, K. H.; Holmes, R. D. Lactate Oxidation for the Detection of Mitochondrial Dysfunction in Human Skin Fibroblasts. Anal. Biochem. 1993, 210, 332-336.
58. Glucose lowering was not expected to be evident in normal animals on the basis of Stacpoole's report (ref 17) and was not observed with compounds of this series in normal animals.